Former Chief Medical Officer · ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Javier San Martin

A named executive officer of ARROWHEAD PHARMACEUTICALS in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$3,456,564

Salary $260,529Stock awards $2,589,750

FY2023: $3,095,982

5th of 6 named executive officers at Arrowhead Pharmaceuticals by FY2024 total.

6 named officers on file for ARROWHEAD PHARMACEUTICALS, FY2024

Javier San Martin’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing
  • ARWR’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ARROWHEAD PHARMACEUTICALS’s whole pay program stands against its peers

  • ARROWHEAD PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ARWR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed January 29, 2025 (DEF 14A).

Free

Get Javier San Martin’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Javier San Martin compensation by year

ARROWHEAD PHARMACEUTICALS Summary Compensation Table · all 2 fiscal years held
In US dollars, as ARROWHEAD PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$544,467$260,529
Bonus$0$0
Stock awards$2,284,800$2,589,750
Option awards$0$0
Non-equity incentive$252,000$0
Pension and deferred compensation$0$0
All other$14,715$606,285
Total$3,095,982$3,456,564

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ARROWHEAD PHARMACEUTICALS, INC. DEF 14A filed January 29, 2025, accession 0001628280-25-002848, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ARROWHEAD PHARMACEUTICALS, INC. filed document, accession 0001628280-25-002848. Every figure is read from that document and cited to the page and table it appears in. Filed January 29, 2025.

$3.1M
$3.5M
FY23
FY24
SalaryNon-equity incentiveStock awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU60,000$1,612,200—
RSU37,500$1,007,625—

Per the Outstanding Equity Awards at Fiscal Year-End table in ARROWHEAD PHARMACEUTICALS, INC.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

ARROWHEAD PHARMACEUTICALS’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Christopher AnzalonePresident and Chief Executive Officer$12,423,473
Patrick O'BrienChief Operating Officer and General Counsel$3,933,570
Kenneth MyszkowskiChief Financial Officer$3,512,376
James HamiltonChief of Discovery and Translational Medicine$3,487,445
Javier San Martin · this pageFormer Chief Medical Officer$3,456,564
Tracie OliverFormer Chief Commercial Officer$3,076,780

The full ARROWHEAD PHARMACEUTICALS compensation record

free company brief

This page is one person within ARROWHEAD PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ARROWHEAD PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ARROWHEAD PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Javier San Martin's compensation dossier · One-time report. No refunds.